医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Open Monoclonal Technology Announces OmniAb™ Alliance with Celgene

2015年03月11日 AM02:06
このエントリーをはてなブックマークに追加


 

PALO ALTO, Calif.

Open Monoclonal Technology, Inc. (OMT) today announced a license that provides Celgene Corporation (Celgene) with unlimited access to OMT’s proprietary OmniRat®, OmniMouse® and OmniFlic™ platforms for generation of human antibody therapeutics.

Dr. Roland Buelow, founder and CEO of OMT, commented, “Celgene is a global leader in novel therapies for cancer and inflammatory diseases where human therapeutic antibodies are particularly useful. The company will become OMT’s 11th partner with unlimited platform access. OMT will facilitate rapid and efficient technology integration into Celgene and believes it will be enabling for the company’s growing pipeline of antibody therapeutics.”

About Open Monoclonal Technology, Inc.

Open Monoclonal Technology, Inc. (OMT) is a leader in genetic engineering of animals for generation of human therapeutic antibodies, naturally optimized human antibodies®, and the only company in the world with four transgenic animal platforms, jointly OmniAb.

OmniRat® is the industry’s first human monoclonal antibody technology based on rats. It has a complete immune system with a diverse antibody repertoire and generates antibodies with human idiotypes as well as wild-type animals make rat antibodies. OmniMouse® is a transgenic mouse that complements OmniRat and expands epitope coverage. OmniFlic is an engineered rat with a fixed light chain for development of bispecific, fully human antibodies. UniRat is the first transgenic rat generating fully human heavy chain-only antibodies and nanobodies for polyspecific applications.

All four OmniAb™ platforms deliver human antibodies with high affinity, specificity, expression, solubility and stability. They use patented technology, have broad freedom to operate and are available worldwide for all targets and indications. Current partners include Celgene, Chugai, Genmab, Genentech, HanAll, Janssen, Merck KGaA, Pfizer, Roche, Symphogen, an undisclosed global pharmaceutical company and several smaller biotech companies and universities. OmniAb antibody discovery services are available via Antibody Solutions in the US, Aldevron in Germany and WuXi AppTec in China.

For more information, please visit www.omtinc.net.

CONTACT

Open Monoclonal Technology, Inc.
Brian Lundstrom, +1-775-420-7750
Chief
Business Officer
bl@omtinc.net

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Takeda to Highlight Broad Oncology Portfolio and Pipeline Data at the American Society of Clinical Oncology (ASCO) and the Congress of the European Hematology Association (EHA) Annual Meetings
  • Cerveau Technologies, Inc.与日本东京都老人综合研究所签订研究协议
  • 继美国和英国之后,中国向Personalis, Inc.签发ACE©技术专利,扩大了其在国际上的知名度
  • セルヴォー・テクノロジーズが日本の東京都健康長寿医療センター研究所と研究契約を締結
  • 国際的な食品・飲料企業の連合が、世界の供給食料から人工トランス脂肪酸を排除するための世界保健機関とResolve to Save Livesによる呼び掛けを支持